<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5Bnlmid%5D&amp;utm_medium = rsss＆ff = 20250411 161211＆utm_content = 101560960＆utm_campaign =期刊＆fc = none＆utm_source = chrome＆v = 2.18.0.post9+e462414<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_medium=rss&amp;ff=20250411161211&amp;utm_content=101560960&amp;utm_campaign=journals&amp;fc=None&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期五，2025年4月11日20:12:12 +0000</lastbuilddate><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>病例报告：用efgartigimod有效治疗了一名与肾衰竭复杂的肌无力的重力患者</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213565/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>肌无力重症（MG）是一种临床特征的神经肌肉连接障碍，其特征是肌肉无力波动，其中一些呼吸道肌肉无力的患者面临着进入重症肌无力危机和呼吸衰竭的风险，需要快速抗体清除治疗。目前使用的静脉内免疫球蛋白和血浆交换疗法在某些患者中仍无效，受到多次禁忌症的限制。 Efgartigimod是新批准的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1526975。 doi：10.3389/fimmu.2025.1526975。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">肌无力重症（MG）是一种临床特征的神经肌肉连接障碍，其特征是肌肉无力波动，其中一些呼吸道肌肉无力的患者面临着进入重症肌无力危机和呼吸衰竭的风险，需要快速抗体清除治疗。目前使用的静脉内免疫球蛋白和血浆交换疗法在某些患者中仍无效，受到多次禁忌症的限制。 Efgartigimod是一种新批准的FCRN拮抗剂，用于治疗肌无力的GRAVIS，该疗法迅速清洁体内的IgG抗体，但仍缺乏在肾脏不足患者中使用efgartigimod的指导。在这里，我们报告了一例患有终末期肾脏疾病的MG患者，经历了维持血液透析，他们成功地导致了肌无力的危机，并通过Efgartigimod治疗实现了重大的临床缓解。此外，持续的Efgartigimod维持治疗能够实现临床最低状态。该病例证明了efgartigimod在伴随肾脏损害的MG患者中的治疗潜力，并提供了支持其在该特殊人群中应用的临床证据。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213565/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213565</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983638/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983638</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1526975>10.3389/fimmu.2025.1526975</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213565</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Jia Ke</dc:creator><dc:creator> Qi Zhao</dc:creator><dc:creator> Na Wang</dc:creator><dc:creator>贝张</dc:creator><dc:creator>Jin-Quan Hu</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>病例报告：用efgartigimod有效治疗了一名与肾衰竭复杂的肌无力的重力患者</dc:title><dc:identifier>PMID：40213565</dc:identifier><dc:identifier> PMC：PMC11983638</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1526975</dc:identifier></item><item><title> NSCLC的新辅助免疫疗法：贝叶斯荟萃分析的优质组合策略，最佳治疗周期和预测指标</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213564/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>结论：新辅助免疫化学疗法与抗血管生成剂联合起来似乎是可切除NSCLC的高效策略。新辅助免疫化学疗法的三个周期在这项研究中表现出最佳功效。 MPR和PCR都是EFS的宝贵预后指标，MPR显示出更强的预测价值。这些发现提供了优化治疗策略并告知可切除NSCLC中临床决策的重要见解。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1548665。 doi：10.3389/fimmu.2025.1548665。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：新辅助免疫检查点抑制剂（ICI）已成为可切除的非小细胞肺癌（NSCLC）的有前途的治疗策略。但是，长期结局的最佳组合策略，治疗周期和预测指标尚不清楚。这项研究旨在评估各种基于新辅助ICI的疗法在可切除的NSCLC中的疗效，确定新辅助免疫化学疗法的最佳治疗周期，并评估病理完全反应（PCR）的预后价值（PCR）的预后价值（PCR）和主要病理学反应（MPR）（MPR）（MPR）的无效生存（EFS）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在PubMed，Embase，Cochrane Central和Web科学上进行了系统的文献搜索，其中包括截至2024年10月的研究。使用贝叶斯模型来分析不同基于ICI的治疗组合的功效，评估Immunochaphemophation Cycles Cycles cym prs和PCR的影响，并检查MPR和PCR的预测值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：包括34项研究的数据，包括32项单臂研究（报道了26篇论文）和8个RCT，涉及4,593名患者。免疫化学疗法与抗血管生成剂相结合是最有效的治疗策略，可显着改善MPR和PCR。当新辅助免疫化学疗法周期超过3个周期时，没有观察到疗效的显着提高。 MPR和PCR都是EFS的强大预测指标。与PCR相比，MPR与事件风险的负相关性更强，对MPR的日志（HR）为-2.110（95％CI：-4.150，-0.071），log（HR）为-1.665（95％CI：-2.419，-0.992）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：新辅助免疫化学疗法与抗血管生成剂联合起来似乎是可切除NSCLC的高效策略。新辅助免疫化学疗法的三个周期在这项研究中表现出最佳功效。 MPR和PCR都是EFS的宝贵预后指标，MPR显示出更强的预测价值。这些发现提供了优化治疗策略并告知可切除NSCLC中临床决策的重要见解。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">系统审查注册：Prospero，标识符CRD42024592346。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213564/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213564</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983614/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983614</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1548665>10.3389/fimmu.2025.1548665</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213564</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Yubingxue刘</dc:creator><dc:creator>江林</dc:creator><dc:creator>汉邓</dc:creator><dc:creator>温陈</dc:creator><dc:date>2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>NSCLC的新辅助免疫疗法：贝叶斯荟萃分析的优质组合策略，最佳治疗周期和预测指标</dc:title><dc:identifier>PMID：40213564</dc:identifier><dc:identifier> PMC：PMC11983614</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1548665</dc:identifier></item><item><title>血小板衍生的代谢产物对嗜中性粒细胞免疫代谢的动态调节</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213563/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>传统上以其在止血和血栓形成中的作用而闻名的血小板已成为免疫反应的关键调节剂，尤其是通过其与中性粒细胞的动态相互作用。这篇评论探讨了血小板如何通过形成血小板中性嗜性骨料，释放细胞外囊泡和分泌代谢物来影响中性粒细胞的功能。这些过程控制着关键的免疫活性，包括细胞募集，激活，内皮相互作用和分辨率... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1542438。 doi：10.3389/fimmu.2025.1542438。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">传统上以其在止血和血栓形成中的作用而闻名的血小板已成为免疫反应的关键调节剂，尤其是通过其与中性粒细胞的动态相互作用。这篇评论探讨了血小板如何通过形成血小板中性嗜性骨料，释放细胞外囊泡和分泌代谢物来影响中性粒细胞的功能。这些过程控制着关键的免疫活性，包括细胞募集，激活，内皮相互作用以及炎症的分辨率或加剧。此外，血小板在中性粒细胞中诱导代谢重编程，影响糖酵解和线粒体途径，同时还通过调节其他免疫细胞（例如T和B细胞）来塑造免疫微环境。了解血液中最丰富的细胞类型的血小板和中性粒细胞之间的这种复杂的串扰揭示了调节炎症和免疫介导疾病中免疫反应的新的治疗机会。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213563/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213563</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983541/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983541</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1542438>10.3389/fimmu.2025.1542438</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213563</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Manuel Alejandro Mosso-Pani</dc:creator><dc:creator>但丁·巴雷达（Dante Barreda）</dc:creator><dc:creator> Ma Isabel Salazar</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>血小板衍生的代谢产物对嗜中性粒细胞免疫代谢的动态调节</dc:title><dc:identifier>PMID：40213563</dc:identifier><dc:identifier> PMC：PMC11983541</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1542438</dc:identifier></item><item><title>全面的泛癌分析表明，p53独立凋亡的关键基因是用于临床应用和结直肠癌化学疗法的新型生物标志物</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213562/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>结论：SLFN11的表达水平具有实质性的希望，作为诊断的有价值的生物标志物，是人类癌症中化学疗法和免疫疗法的有效性的预测指标，这值得进一步的基本实验和临床试验证明。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1571137。 doi：10.3389/fimmu.2025.1571137。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：Schlafen11（Slfn11）是通过核糖体停滞的p53非依赖性凋亡中的关键基因。然而，已经对其在泛滥症中的肿瘤免疫微环境，临床应用和免疫疗法反应中进行了系统研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：下载了公共数据，并使用多词的方法来研究SLFN11的表达水平与空间位置，生物功能，免疫景观和临床应用值之间的关系。细胞计数KIT-8测定和定量实时PCR用于验证大肠癌样品中SLFN11的表达水平和药物敏感性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们的研究表明，大多数癌症中SLFN11被下调，并与DNA修复，p53途径和免疫反应在肿瘤发育进展中通过多摩卡分析相关。失调的SLFN11伴随着几种免疫细胞浸润和免疫相关的调节剂，这可能是有希望的筛查和预后的生物标志物和化学疗法预测性的临床应用靶标。<i>体外</i>实验证明，下调的SLFN11是一种有用的诊断生物标志物，与结直肠癌的伊马替尼抗性有关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：SLFN11的表达水平具有实质性的希望，作为诊断的有价值的生物标志物，是人类癌症中化学疗法和免疫疗法的有效性的预测指标，这值得进一步的基本实验和临床试验证明。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213562/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213562</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983446/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983446</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1571137>10.3389/fimmu.2025.1571137</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213562</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator>简元</dc:creator><dc:creator>Jingzhi Wang</dc:creator><dc:creator> min miao</dc:creator><dc:creator> Yongfu Shao</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>全面的泛癌分析表明，p53独立凋亡的关键基因是用于临床应用和结直肠癌化学疗法的新型生物标志物</dc:title><dc:identifier>PMID：40213562</dc:identifier><dc:identifier> PMC：PMC11983446</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1571137</dc:identifier></item><item><title> Vδ2T细胞对Th2样表型的极化促进了浆膜分化，并具有与IgG4相关疾病的促纤维化特性</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213561/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>结论：在IgG4-RD的IL-21富含微环境中，周围Vδ2T细胞通过IL-21-STAT3-BLIMP-1-GATA3途径获得Th2样表型。靶向JAK/STAT3抑制剂具有IgG4-RD的治疗潜力。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1550405。 doi：10.3389/fimmu.2025.1550405。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：探索γ三角（γδ）T细胞在IgG4相关疾病（IgG4-RD）发病机理中的表型和作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用流式细胞仪和定量RT-PCR来分析γδT细胞亚群，趋化因子受体表达，细胞因子产生，促纤维化基因表达和转录因子谱分析。免疫荧光评估了受影响组织中的Vδ2T细胞浸润。趋化测定和共培养实验研究了Vδ2T细胞迁移及其对B细胞分化的影响。还评估了IL-21刺激和JAK/STAT3抑制剂对γδT细胞的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：IgG4-RD患者表现出降低的外周Vδ2T细胞，其表现为Th2样表型，其特征是Th2细胞因子产生升高并激活IL-21-STAT3-BLIMP-1-GATA3途径。 VΔ2T细胞通过CCR7上调积聚在受影响的组织中，并与B细胞共定位。 IgG4-RD患者的VΔ2T细胞和培养上清液都促进了B细胞分化。 IL-21刺激增强了VΔ2T细胞中的PSTAT3，Blimp-1和GATA3表达，而JAK和STAT3抑制剂减弱了这些作用。 IgG4-RD患者在γδT细胞中表现出增加的TGF-β和促纤维化基因表达。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在IgG4-RD的IL-21富含微环境中，周围Vδ2T细胞通过IL-21-STAT3-BLIMP-1-GATA3途径获得Th2样表型。靶向JAK/STAT3抑制剂具有IgG4-RD的治疗潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213561/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213561</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983612/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983612</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1550405>10.3389/fimmu.2025.1550405</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213561</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Jieqiong li</dc:creator><dc:creator>王王</dc:creator><dc:creator>Jiaxin Zhou</dc:creator><dc:creator> Yunyun Fei</dc:creator><dc:creator> Mengtao li</dc:creator><dc:creator> Yan Zhao</dc:creator><dc:creator> Zeng Zeng</dc:creator><dc:creator> Linyi Peng</dc:creator><dc:creator>温张</dc:creator><dc:date>2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>Vδ2T细胞对Th2样表型的极化促进了浆膜分化，并具有与IgG4相关疾病的促纤维化特性</dc:title><dc:identifier>PMID：40213561</dc:identifier><dc:identifier> PMC：PMC11983612</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1550405</dc:identifier></item><item><title>在Covid-19的不同波浪中，住院患者的炎症反应和预后差异差异</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213560/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>结论：这项研究强调了Covid-19的动态性质，对生物标志物趋势进行了详细分析，这些趋势可以为早期鉴定有严重结果的患者提供有价值的信息，从而及时进行干预。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1545181。 doi：10.3389/fimmu.2025.1545181。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：这项研究的目的是评估炎症生物标志物的差异及其与住院治疗的2019年冠状病毒疾病患者的结局（COVID-19），这是在不同的SARSCOV-2-2种关注变体确定的大流行波中。我们探讨了炎症的实验室生物标志物是否适应患者的合并症，年龄和疫苗接种状况与严重程度和死亡率相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：一项关于8,614例住院Covid-19患者的回顾性研究，在罗马尼亚一家医院进行了3年的间隔（2020年2月至2023年5月）。 Data collected included demographics, duration of hospitalization, comorbidities, vaccination status, COVID-19 severity, outcome, and markers of inflammation from the first blood test performed at admittance [C-reactive protein (CRP), fibrinogen, ferritin, lactate dehydrogenase (LDH), procalcitonin (PCT), IL-6, D-dimer, and complete blood count].诸如中性粒细胞与淋巴细胞比例（NLR），衍生的嗜中性粒细胞与淋巴细胞比（DNLR），淋巴细胞与单位细胞与单位细胞比率（LMR），基质与淋巴细胞比率（Pllymphocyte（Pllymphocior），中性倍增和倍增症（NPR）（NPR）（NPR）（NPR）（NPR）（NPR）（NPR））（NLR）（LMR）（LMR）（LMR）（LMR）（LMR）（LMR）（NPR）（NPR）（NPR））（NLR）（DNLR）（LMR）（NPR）计算（SII）和全身炎症反应指数（SIRI）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：三角波的特征是住院时间最长，严重病例和死亡率最高，显示出炎症生物标志物的显着升高。 CRP，纤维蛋白原，铁蛋白，IL-6，D-二聚体和LDH的中位数从武汉到三角波的中值增加，并且在Omicron波中减少了PCT，除PCT外，从Alpha增加到Omicron Wave。白细胞和中性粒细胞的中位数从武汉到三角波的中位数增加，在Omicron波中减少，而淋巴细胞，单核细胞和嗜碱性粒细胞可以观察到逆模式。预测严重/关键Covid-19的最佳炎症生物标志物是CRP，DNLR，LDH和NLR（分别为3.41 mg/dl，3.05、262 U/L和4.5），而预测最佳生物标志物是DNLR，NLR，NLR，LDH和NPR（4.和NPR），以及4.和Npr（4.分别为0.02）。对于所有这些生物标志物，曲线（AUC）下的区域均超过0.8。在多变量分析中，描述了DNLR（8.46），NLR（7.59），LDH（5.99）和NPR（5.5）的最高调整或死亡，而淋巴细胞的增加降低了最高的调整或死亡（0.16）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究强调了Covid-19的动态性质，对生物标志物趋势进行了详细分析，这些趋势可以为早期鉴定有严重结果的患者提供有价值的信息，从而及时进行干预。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213560/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213560</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983512/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983512</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1545181>10.3389/fimmu.2025.1545181</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213560</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Violeta Briciu</dc:creator><dc:creator> Daniel-Corneliu Leucuta</dc:creator><dc:creator>莫妮卡·蒙特尼（Monica Muntean）</dc:creator><dc:creator> Amanda Radulescu</dc:creator><dc:creator>克里斯蒂娜·西马鲁（Cristina Cismaru）</dc:creator><dc:creator> Adriana Topan</dc:creator><dc:creator>露西亚·赫尔贝尔（Lucia Herbel）</dc:creator><dc:creator>梅琳达·霍瓦特（Melinda Horvat）</dc:creator><dc:creator> Mirela Flonta</dc:creator><dc:creator> Mihai Calin</dc:creator><dc:creator> Roxana Dobrota</dc:creator><dc:creator> Mihaela Lupse</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>在Covid-19的不同波浪中，住院患者的炎症反应和预后差异差异</dc:title><dc:identifier>PMID：40213560</dc:identifier><dc:identifier> PMC：PMC11983512</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1545181</dc:identifier></item><item><title> CLEC12A指导的免疫细胞因子具有靶细胞限制的IL-15活性，用于治疗急性髓样白血病</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213559/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>尽管最近进步，急性髓性白血病（AML）仍然是一个治疗挑战。尽管通过抗体依赖性细胞毒性利用天然杀伤细胞（NK）细胞的单克隆抗体（MABS）具有巨大的潜力，但没有一个获得AML的临床认可。免疫细胞因子已经成为克服治疗抗体有限效力的有希望的策略。 IL-15刺激了NK细胞的激活，增殖的细胞毒性活性，但它的临床用途得到了阻止... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1561823。 doi：10.3389/fimmu.2025.1561823。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">尽管最近进步，急性髓性白血病（AML）仍然是一个治疗挑战。尽管通过抗体依赖性细胞毒性利用天然杀伤细胞（NK）细胞的单克隆抗体（MABS）具有巨大的潜力，但没有一个获得AML的临床认可。免疫细胞因子已经成为克服治疗抗体有限效力的有希望的策略。 IL-15刺激了NK细胞的激活，增殖的细胞毒性活性，但是由于半衰期短，肿瘤积累较差以及由于全身性脱靶免疫激活而导致的毒性可防止其临床使用。在这里，我们报告了由FC优化的CLEC12A（CLL-1）抗体组成的改性免疫细胞动力油的产生和临床前表征，该抗体融合了具有E46K突变的IL-15部分。该突变消除了与IL-15Rα的结合，从而通过靶结合替代了生理跨表达，从而实现了有条件的IL-15Rβ/γ刺激以降低全身毒性。基于对患者的AML细胞系和白血病细胞的分析，从一系列鼠mAB中选择了最佳CLEC12A粘合剂。然后，该抗体用于构建一种免疫细胞因子（MIC12），随后在功能上表征了该抗体。 NK细胞活化，细胞因子释放，增殖和抗白血病反应性的分析表明，与FC优化的CLEC12A抗体相比，MIC12诱导了上靶细胞杀伤和NK细胞的扩张，其功效取决于靶抗原结合。我们的结果表明，具有条件IL-15活性的新型免疫细胞因子能够诱导针对AML细胞的有效NK细胞反应，并将MIC12识别为白血病治疗的有希望的治疗候选。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213559/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213559</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983603/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983603</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1561823>10.3389/fimmu.2025.1561823</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213559</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Boris Klimovich</dc:creator><dc:creator>伦纳德·安东</dc:creator><dc:creator>金旺·荣格（Jinwon Jung）</dc:creator><dc:creator> Yangmi lim</dc:creator><dc:creator> Bora Lee</dc:creator><dc:creator> Jonghwa获胜</dc:creator><dc:creator>Latifa Zekri</dc:creator><dc:creator>安娜·查奇纳（Anna Chashchina）</dc:creator><dc:creator>马丁·普夫勒（MartinPflügler）</dc:creator><dc:creator>乔纳斯·赫特曼（Jonas s Heitmann）</dc:creator><dc:creator> Gundram Jung</dc:creator><dc:creator> Helmut R Salih</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>CLEC12A指导的免疫细胞因子具有靶细胞限制的IL-15活性，用于治疗急性髓样白血病</dc:title><dc:identifier>PMID：40213559</dc:identifier><dc:identifier> PMC：PMC11983603</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1561823</dc:identifier></item><item><title>对天然化合物的筛查和机械研究，从而增强T细胞抗肿瘤效应后热处理</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213558/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>简介：在多个国家批准了嵌合抗原受体T细胞免疫疗法（CAR-T）之后，食品药物管理局（FDA）批准了今年今年今年今年的肿瘤浸润淋巴细胞（TILS）和T-Cell受体工程T细胞（TCR-T）治疗。在肿瘤治疗中使用过免疫疗法的利用变得越来越突出。优化在体外培养条件下免疫细胞的细胞毒性作用代表了当前的热门研究主题。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1537398。 doi：10.3389/fimmu.2025.1537398。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：在多个国家批准了嵌合抗原受体T细胞免疫疗法（CAR-T）之后，食品药物管理局（FDA）批准了今年今年今年今年的肿瘤浸润淋巴细胞（TILS）和T-Cell受体工程T细胞（TCR-T）治疗。在肿瘤治疗中使用过免疫疗法的利用变得越来越突出。在<i>体外</i>培养条件下优化免疫细胞的细胞毒性作用代表了该领域中当前的热研究主题。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在当前的实验中，我们在39°C的Jurkat衍生的T细胞上进行了<i>体外</i>热处理。在此基础上，我们利用了九种不同的可注射溶液和超过70种中医（TCM）的单体组成部分。随后，我们与K562-EGFP细胞共同培养了这些处理过的Jurkat细胞，并使用Incucyte Live细胞分析系统实时监测共培养过程。同样重要的是，我们结合了HIMAP高通量转录组测序，蛋白质组学和代谢组学以进行深入检查。我们筛选了具有抗肿瘤特性的化合物，并彻底研究了它们的作用机理。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果和讨论：发现表明，加热处理增加了Jurkat细胞对恶性肿瘤的细胞毒性作用，并且当T细胞暴露于39°C 24小时的时间为39°C时，达到了最佳作用（与37°C治疗相比，细胞增殖率增加了48％）。通过触发热激蛋白的产生并促进线粒体能量供应，39°C的处理扩增了T细胞的抗肿瘤功能。通过分析数据，我们确定了3种注射溶液和20多个有效的单体，能够进一步增强T细胞的肿瘤杀伤能力。高通量转录组学研究表明，热疗和TCM的组合促进了Jurkat细胞的Jurkat细胞增殖，激活和细胞毒性功能，从而激活了有丝分裂细胞周期的调节以发挥抗肿瘤作用。转录组和蛋白质组学数据的整合表明，Shengmai注射可显着增强Jurkat细胞的肿瘤杀伤作用，通过下调凋亡的调节和有丝分裂细胞周期信号通路的调节。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213558/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213558</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983556/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983556</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1537398>10.3389/fimmu.2025.1537398</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213558</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Zhaoyi Wang</dc:creator><dc:creator> Zhongqi diao</dc:creator><dc:creator> Yiyan Zhang</dc:creator><dc:creator>刘刘</dc:creator><dc:creator>Yeshan li</dc:creator><dc:creator> Zijin Sun</dc:creator><dc:creator> Huimin Zhen</dc:creator><dc:creator> Haojia Wang</dc:creator><dc:creator>西扬阳</dc:creator><dc:creator>Tieshan Wang</dc:creator><dc:creator> Lei ni</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>对天然化合物的筛查和机械研究，从而增强T细胞抗肿瘤效应后热处理</dc:title><dc:identifier>PMID：40213558</dc:identifier><dc:identifier> PMC：PMC11983556</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1537398</dc:identifier></item><item><title>嵌合受体结合结构域疫苗的设计和顺序免疫增强了对COVID-19的广泛中和抗体反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213557/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>简介：使用改良的使者RNA（mRNA）技术开发的疫苗对人类的严重急性呼吸综合症2（SARS-COV-2）感染表现出强大的效率。但是，由于具有强大免疫渗透能力的新变体的出现，人类和非人类宿主的病毒演化可能会损害疫苗性能。因此，2019年冠状病毒病（COVID-19）疫苗可诱导高水平的广泛中和抗体（BNAB）并迅速反应... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1543212。 doi：10.3389/fimmu.2025.1543212。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：使用改良的使者RNA（mRNA）技术开发的疫苗对人类的严重急性呼吸综合症2（SARS-COV-2）感染表现出强大的效率。但是，由于具有强大免疫渗透能力的新变体的出现，人类和非人类宿主的病毒演化可能会损害疫苗性能。因此，紧急迫切需要一种诱导高水平中和的抗体（BNAB）的冠状病毒疾病（Covid-19）疫苗，该疫苗紧急需要迅速对病毒突变做出反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这里，我们基于关注（VOC）SPIKE（S）蛋白受体结合结构域（RBD）嵌合的变体设计了一种二价mRNA疫苗RBDCO，来自不同谱系与FC片段融合的嵌合。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在小鼠和非人类灵长类动物中，RBDCO有效地诱导了针对多个假病毒的中和抗体，包括可能的流行病XBB.1，XBB.1.9.1和EA.1伪病毒。在小鼠中，RBDCO针对来自不同谱系的11个SARS-COV-2变异病毒诱导BNAB。针对原型D614G和流行病XBB.1.16的中和抗体滴度分别为19666年和13274。 RBDCO诱导的小鼠在刺激SARS-COV-2变体的RBD蛋白下分泌干扰素-γ（IFN-γ）。在小鼠挑战模型中，RBDCO治疗导致挑战后小鼠肺的病毒负荷降低了10倍。这些结果表明，RBDCO可以在动物中诱导BNAB反应和细胞免疫反应，从而阻止COVID-19的发生。此外，顺序免疫结果显示，相对于灭活组，在RBDCO促进基团中有改善的中和抗体滴度。在RBDCO增强的组中观察到了记忆T细胞的分化增强。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：总体而言，RBDCO可以通过嵌合RBD诱导动物的BNAB，并在不同的谱系中使用SARS-COV-2 VOC诱导BNAB，并且是mRNA疫苗对病毒突变的快速反应的候选者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213557/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213557</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983632/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983632</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1543212>10.3389/fimmu.2025.1543212</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213557</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator>小杨</dc:creator><dc:creator>Xin Tang</dc:creator><dc:creator>太阳</dc:creator><dc:creator>hualong xi</dc:creator><dc:creator>魏彭</dc:creator><dc:creator>lu yan</dc:creator><dc:creator> Wenjing Teng</dc:creator><dc:creator>杨赞</dc:creator><dc:creator>Chunlai Jiang</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>嵌合受体结合结构域疫苗的设计和顺序免疫增强了对COVID-19的广泛中和抗体反应</dc:title><dc:identifier>PMID：40213557</dc:identifier><dc:identifier> PMC：PMC11983632</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1543212</dc:identifier></item><item><title>助推器克服了COVID-19疫苗的扩展抗剂量间隔的改进抗体宽度</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213556/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>简介：在推出基于mRNA的COVID-19疫苗期间，几个司法管辖区扩大了第一剂和第二剂之间的间隔，以优先考虑更广泛的人群获得有限的疫苗供应。这项研究评估了剂量间隔对初级剂量系列后抗体和细胞介导的反应发展的影响以及随后的增强剂量。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1529134。 doi：10.3389/fimmu.2025.1529134。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：在推出基于mRNA的COVID-19疫苗期间，几个司法管辖区扩大了第一剂和第二剂之间的间隔，以优先考虑更广泛的人群获得有限的疫苗供应。这项研究评估了剂量间隔对初级剂量系列后抗体和细胞介导的反应发展的影响以及随后的增强剂量。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：每次剂量后，从基线和纵向上从mRNA Covid-19疫苗接受者那里收集血液样本。分析样品中的SARS-COV-2特异性抗体滴度，中和抗体和记忆T细胞反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：扩展剂量间隔与对祖先和早期SARS-COV-2变体的中和抗体反应的广度有关，而不是Omicron变体。剂量间隔对抗原特异性记忆T细胞反应，反应T细胞或细胞因子产生的记忆或T辅助表型没有影响。第三剂量mRNA疫苗后，初级剂量间隔对免疫结局的影响不再明显。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：延长的初级剂量间隔导致了对体液免疫的短期益处，但在随后的暴露范围内是短暂的。但是，除了人口更广泛地获得疫苗的公共卫生益处外，在没有助推器的情况下，扩大剂量间隔的短期免疫学益处可能已经维持。这些发现强调了在未来候选疫苗的开发过程中评估给药间隔的重要性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40213556/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213556</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983636/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983636</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1529134>10.3389/fimmu.2025.1529134</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40213556</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator>杰西卡我艾哈迈德</dc:creator><dc:creator>Samantha J Krosta</dc:creator><dc:creator> Mandy N Reimer</dc:creator><dc:creator> Winnie Cheung</dc:creator><dc:creator>克里斯汀·梅萨</dc:creator><dc:creator>卡门·洛佩兹（Carmen Lopez）</dc:creator><dc:creator> Rayeil J Chua</dc:creator><dc:creator>法拉·阿尔萨里（Farah Alsattari）</dc:creator><dc:creator> Alyssia Robinson</dc:creator><dc:creator>凯西·曼吉亚特（Kathy Manguiat）</dc:creator><dc:creator> Naima Jahan</dc:creator><dc:creator>伯纳德·阿伯尼卡（Bernard Abrenica）</dc:creator><dc:creator>安吉拉·哈里斯（Angela Harris）</dc:creator><dc:creator> Karla Cachero</dc:creator><dc:creator> Rissa Fabia</dc:creator><dc:creator>乔纳森·沃克（Jonathan Walker）</dc:creator><dc:creator> myo minn oo</dc:creator><dc:creator>德里克·斯坦</dc:creator><dc:creator>hezhao ji</dc:creator><dc:creator> Ruey-Chyi Su</dc:creator><dc:creator>保罗·J·麦克拉伦（Paul J McLaren）</dc:creator><dc:creator>莱尔·麦金农（Lyle R McKinnon）</dc:creator><dc:creator> t布雷克球</dc:creator><dc:creator>海蒂·伍德</dc:creator><dc:creator>约翰·金</dc:creator><dc:creator>Sandra A Kiazyk</dc:creator><dc:creator>凯瑟琳M卡</dc:creator><dc:date>2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>助推器克服了COVID-19疫苗的扩展抗剂量间隔的改进抗体宽度</dc:title><dc:identifier>PMID：40213556</dc:identifier><dc:identifier> PMC：PMC11983636</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1529134</dc:identifier></item><item><title>血清中的尖峰特异性IgG3和核素IgG反应可作为区分SARS-COV-2感染与疫苗接种之间的免疫学标记</title><link/>https://pubmed.ncbi.nlm.nih.gov/40213555/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250411161211＆v = 2.18.0.post9+e462414<description>结论：这些发现突出了RBD特异性IgG3以及核包皮IgG作为与疫苗接种和自然感染区分区分的关键标记，并表明这些测定法具有纵向监测疫苗接种并确定SARS-COV-2相关的保护物。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月27日； 16：1518915。 doi：10.3389/fimmu.2025.1518915。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：SARS-COV-2感染和COVID-19疫苗都引起免疫反应。但是，很难区分疫苗接种与自然感染后产生的反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们研究了SARS-COV-2尖峰受体结合结构域（RBD）和Nucleocapsid特异性IgG和RBD特异性IgG亚类（IgG1，IgG1，IgG2，IgG3和IgG4）响应，使用ELISA使用ELISA使用ELISA进行四种不同的组中； (1) COVID-19 patients (n=39) with varying disease severity and (2) COVID-19 vaccinated individuals (n=24, both adenovirus/mRNA based) (3) vaccinated after infection (n=39) and (4) patients experienced breakthrough infection (n=14), in Bangladesh. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Both COVID-19 patients and vaccinees developed robust RBD-specific IgG responses. In contrast, nucleocapsid specific IgG responses were found in patients but not in vaccine recipients. A distinct IgG subclass antibody response was observed in COVID-19 patients compared to COVID-19-vaccinated individuals. Specifically, COVID-19 patients exhibited elevated levels of both IgG1 and IgG3, with IgG3 dominating in the early phase of infection (days 1-7) followed by a subsequent increase in IgG1. Conversely, COVID-19 vaccination predominantly induced IgG1 responses without a concurrent rise in IgG3. This effect was more evident when a significant rise of IgG1 but not IgG3 was observed in patients who received COVID-19 vaccines after 90 days of infection. However, following breakthrough infection, we observed an increase in both IgG1 and IgG3. All of these findings collectively indicate that COVID-19 vaccination predominantly induces IgG1, whereas natural infection can elicit responses in both IgG1 and IgG3 subclasses. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: The findings highlight RBD-specific IgG3 as well as nucleocapsid IgG as crucial markers for differentiating between vaccination and natural infection and suggest these assays have utility for longitudinal monitoring of vaccinations and for establishing SARS-CoV-2 correlates of protection.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40213555/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213555</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983542/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983542</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1518915>10.3389/fimmu.2025.1518915</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40213555</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Marjahan Akhtar</dc:creator><dc:creator> Md Rashedul Islam</dc:creator><dc:creator> Fatema Khaton</dc:creator><dc:creator> Fatima Rahman</dc:creator><dc:creator> Tausif Adnan Sami</dc:creator><dc:creator> Imam Tauheed</dc:creator><dc:creator> Tasnuva Ahmed</dc:creator><dc:creator> Afroza Akter</dc:creator><dc:creator> Ishtiakul Islam Khan</dc:creator><dc:creator> Zahid Hasan Khan</dc:creator><dc:creator> Prasanta Kumar Biswas</dc:creator><dc:creator> Edward T Ryan</dc:creator><dc:creator> Sayera Banu</dc:creator><dc:creator> Tahmina Shirin</dc:creator><dc:creator> Fahima Chowdhury</dc:creator><dc:creator> Ashraful Islam Khan</dc:creator><dc:creator> Taufiqur Rahman Bhuiyan</dc:creator><dc:creator> Firdausi Qadri</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>Spike specific IgG3 and nucleocapsid IgG response in serum serve as distinguishing immunological markers between SARS-CoV-2 infection and vaccination</dc:title><dc:identifier> pmid:40213555</dc:identifier><dc:identifier> pmc:PMC11983542</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1518915</dc:identifier></item><item><title> Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar</title><link/> https://pubmed.ncbi.nlm.nih.gov/40213554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250411161211&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: These findings underscore the importance of booster vaccination in enhancing anti-viral immunity across both infection-naïve and previously infected individuals, enhancing distinct arms of the anti-viral immune response and prolonging naturally acquired immunity. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 27;16:1557426. doi: 10.3389/fimmu.2025.1557426.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: In March 2020, the rapid spread of SARS-CoV-2 prompted global vaccination campaigns to mitigate COVID-19 disease severity and mortality. The 2-dose BNT162b2-mRNA vaccine effectively reduced infection and mortality rates, however, waning vaccine effectiveness necessitated the introduction of a third vaccine dose or booster. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> AIM: To assess the magnitude and longevity of booster-induced immunity, we conducted a longitudinal study of SARS-CoV-2 specific cellular and humoral immune responses among Qatar&#39;s vulnerable craft and manual worker community. We also investigated the impact of prior naturally acquired immunity on booster vaccination efficacy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Seventy healthy participants were enrolled in the study, of whom half had prior SARS-CoV-2 infection. Blood samples were collected before and after booster vaccination to evaluate immune responses through SARS-CoV-2 specific ELISpots, IgG ELISA, neutralization assays, and flow cytometric immunophenotyping. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: T cell analysis revealed increased Th1 cytokine responses, marked by enhanced IFN-γ release, in recently infected participants, which was further enhanced by booster vaccination for up to 6-months. Furthermore, booster vaccination stimulated cytotoxic responses in infection-naïve participants, characterized by granzyme B production. Both natural SARS-CoV-2 infection and booster vaccination induced robust and durable SARS-CoV-2 specific humoral immune responses, with high neutralizing antibody levels. Prior natural infection was also linked to an increased number of class-switched B cells prior to booster vaccination. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: These findings underscore the importance of booster vaccination in enhancing anti-viral immunity across both infection-naïve and previously infected individuals, enhancing distinct arms of the anti-viral immune response and prolonging naturally acquired immunity.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40213554/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213554</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983602/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983602</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1557426>10.3389/fimmu.2025.1557426</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40213554</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Remy Thomas</dc:creator><dc:creator> Ahmed Zaqout</dc:creator><dc:creator> Bakhita Meqbel</dc:creator><dc:creator> Umar Jafar</dc:creator><dc:creator> Nishant N Vaikath</dc:creator><dc:creator> Abdullah Aldushain</dc:creator><dc:creator> Adviti Naik</dc:creator><dc:creator> Hibah Shaath</dc:creator><dc:creator> Neyla S Al-Akl</dc:creator><dc:creator> Abdi Adam</dc:creator><dc:creator> Houda YA Moussa</dc:creator><dc:creator> Kyung C Shin</dc:creator><dc:creator> Rowaida Z Taha</dc:creator><dc:creator> Mohammed Abukhattab</dc:creator><dc:creator> Muna A Almaslamani</dc:creator><dc:creator> Nehad M Alajez</dc:creator><dc:creator> Abdelilah Arredouani</dc:creator><dc:creator> Yongsoo Park</dc:creator><dc:creator> Sara A Abdulla</dc:creator><dc:creator> Omar MA El-Agnaf</dc:creator><dc:creator> Ali S Omrani</dc:creator><dc:creator> Julie Decock</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>Longitudinal cellular and humoral immune responses following COVID-19 BNT162b2-mRNA-based booster vaccination of craft and manual workers in Qatar</dc:title><dc:identifier> pmid:40213554</dc:identifier><dc:identifier> pmc:PMC11983602</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1557426</dc:identifier></item><item><title> Glucocorticoid boluses followed by tocilizumab in giant cell arteritis patients: effects on peripheral blood monocytes and lymphocytes</title><link/> https://pubmed.ncbi.nlm.nih.gov/40213553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250411161211&amp;v=2.18.0.post9+e462414<description> CONCLUSION: GC boluses modified the relative percentages of lymphocyte and monocyte subsets and modified the expression levels of CCR2, CX3CR1, and HLA-DR in monocytes. These changes may contribute to the anti-inflammatory effects of GCs. TCZ monotherapy had more limited effects. Changes in CCR2 expression by intermediate monocytes might have a prognostic value in LVV. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 27;16:1516008. doi: 10.3389/fimmu.2025.1516008.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Giant Cell Arteritis (GCA) is the most common vasculitis in the elderly, characterized by granulomatous infiltration of immune cells in medium and large arteries. A therapeutic protocol that combines ultra-short glucocorticoids (GC) followed by tocilizumab (TCZ) monotherapy has been proven effective in GCA patients with extracranial large vessel involvement (LV-GCA). However, its effects on circulating immune cells are unknown. The aim of this study was to deepen the understanding of the immunological mechanisms behind this treatment regimen in patients with LV-GCA. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: 15 patients with active LV-GCA were included in this study. Blood samples were collected at baseline, after 3 days of GC treatment, at weeks 24 and 52 during TCZ monotherapy, and at week 78 after the suspension of TCZ. Peripheral blood mononuclear cells were isolated from blood samples. The percentages of lymphocyte and monocyte subsets and the expression of the monocyte markers CCR2, CX3CR1, and HLA-DR were analyzed by flow cytometry. Paired Student&#39;s t-test and mixed-effects analysis were used for the comparison between and among groups, respectively. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: GC boluses increased the percentages of B lymphocytes and classical monocytes while decreased those of CD4+ T lymphocytes and intermediate and non-classical monocytes. Moreover, GC boluses increased CCR2 and decreased HLA-DR and CX3CR1 expression by monocytes. TCZ induced a reduction in CCR2 expression versus baseline in classical and intermediate monocytes. Patients with higher reduction in CCR2 expression in intermediate monocytes at 24 weeks and 52 weeks versus baseline showed signs of disease activity at 78 weeks. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: GC boluses modified the relative percentages of lymphocyte and monocyte subsets and modified the expression levels of CCR2, CX3CR1, and HLA-DR in monocytes. These changes may contribute to the anti-inflammatory effects of GCs. TCZ monotherapy had more limited effects. Changes in CCR2 expression by intermediate monocytes might have a prognostic value in LVV.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40213553/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213553</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983418/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983418</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1516008>10.3389/fimmu.2025.1516008</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40213553</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Cecilia Catellani</dc:creator><dc:creator> Martina Bonacini</dc:creator><dc:creator> Alessandro Rossi</dc:creator><dc:creator> Ilaria Ferrigno</dc:creator><dc:creator> Veronica Buia</dc:creator><dc:creator> Chiara Marvisi</dc:creator><dc:creator> Giulia Cassone</dc:creator><dc:creator> Mariagrazia Catanoso</dc:creator><dc:creator> Gabriella Di Tommaso</dc:creator><dc:creator> Luigi Boiardi</dc:creator><dc:creator> Rexhep Durmo</dc:creator><dc:creator> Annibale Versari</dc:creator><dc:creator> Massimiliano Casali</dc:creator><dc:creator> Giulia Besutti</dc:creator><dc:creator> Lucia Spaggiari</dc:creator><dc:creator> Alessandro Zerbini</dc:creator><dc:creator> Francesco Muratore</dc:creator><dc:creator> Carlo Salvarani</dc:creator><dc:creator> Stefania Croci</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>Glucocorticoid boluses followed by tocilizumab in giant cell arteritis patients: effects on peripheral blood monocytes and lymphocytes</dc:title><dc:identifier> pmid:40213553</dc:identifier><dc:identifier> pmc:PMC11983418</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1516008</dc:identifier></item><item><title> Melanocortin-1 receptor expression as a predictive factor for postoperative outcomes in melanoma patients: a retrospective study</title><link/> https://pubmed.ncbi.nlm.nih.gov/40213552/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250411161211&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Low MC1R expression in melanoma tumor tissues and adjacent normal tissue might be beneficial for the prognosis of melanoma patients. MC1R was a predictive factor for the prognosis of melanoma patients. Nomogram models based on MC1R demonstrated good prediction ability. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 27;16:1570502. doi: 10.3389/fimmu.2025.1570502.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND OBJECTIVE: This study aims to explore the relationship between melanocortin-1 receptor (MC1R) expression levels and clinical pathological parameters of melanoma, as well as its potential as a prognostic biomarker. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This retrospective study included 99 melanoma patients in our hospital from June 2017 to July 2023. MC1R expression was assessed by immunohistochemistry assays. Histochemistry score (H-score) determined the level of MC1R immunohistochemistry expression in melanoma. The relationships among MC1R expression, clinical pathological parameters in melanoma patients were assessed using Chi-square and Fisher&#39;s precision probability tests. Kaplan-Meier assay and log-rank test were utilized to estimate survival curves. Potential independent factors among the enrolled patients were investigated using COX regression analysis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: According to median value of H-score, 38 cases with low MC1R expression and 61 cases with high MC1R expression in melanoma tumor tissues were observed. Patients with high MC1R expression in melanoma tissues exhibited a worse prognosis compared to patients with low MC1R expression. The survival time difference was statistically significant [MC1R expression in melanoma tumor tissue (MC1RT): median DFS, 12.83 vs. 17.53 months, χ2 = 5.395, P=0.0202; median OS, 16.47 vs. 21.77 months, χ2 = 5.082, P=0.0243. MC1R expression in normal adjacent to melanoma tissue (MC1RN): median DFS, 12.03 vs. 14.29 months, χ2 = 6.864, P=0.0088; median OS, 16.73 vs. 21.77 months, χ2 = 5.649, P=0.0175]. Multivariate COX regression model analysis indicated that MC1RN, MC1RT, sex, ESR, tumor site, targeted therapy, and immunotherapy were potential prognostic factors for the DFS. Furthermore, MC1RN, MC1RT, sex, tumor site, TLN, PLN, and immunotherapy were potential prognostic factors for the OS. Calibration curve indicated the predicted probabilities of nomogram models were in accordance with the actual probabilities, and the prediction accuracy was relatively high at one year and three years following surgery. The decision clinical curve revealed that the nomogram models had better predictive performance for DFS and OS than the MC1RT or MC1RN thresholds. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Low MC1R expression in melanoma tumor tissues and adjacent normal tissue might be beneficial for the prognosis of melanoma patients. MC1R was a predictive factor for the prognosis of melanoma patients. Nomogram models based on MC1R demonstrated good prediction ability.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40213552/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213552</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983465/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983465</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1570502>10.3389/fimmu.2025.1570502</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40213552</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Tian Xiang</dc:creator><dc:creator> Haiying Li</dc:creator><dc:creator> Xiaowei Wang</dc:creator><dc:creator> Danke Su</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>Melanocortin-1 receptor expression as a predictive factor for postoperative outcomes in melanoma patients: a retrospective study</dc:title><dc:identifier> pmid:40213552</dc:identifier><dc:identifier> pmc:PMC11983465</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1570502</dc:identifier></item><item><title> A system review of neoadjuvant immune checkpoint blockade for breast cancer</title><link/> https://pubmed.ncbi.nlm.nih.gov/40213551/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250411161211&amp;v=2.18.0.post9+e462414<description> CONCLUSION: The combination of ICB with conventional neoadjuvant treatment is associated with favorable clinical outcomes and importantly, increased grade 3+ toxicities. Clinicians should meticulously monitor patients to minimize the risk of treatment discontinuation in individuals with potentially curable breast cancer. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 27;16:1537926. doi: 10.3389/fimmu.2025.1537926.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The clinical application of immune checkpoint blockade (ICB)-based neoadjuvant therapy has been approved in breast cancer since 2021. However, no studies have evaluated its efficacy and safety in randomized and non-randomized settings. Additionally, there exists controversy about which specific subpopulation can benefit from this management strategy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We searched MEDLINE and EMBASE databases for prospective clinical trials of ICB-based neoadjuvant therapy in breast cancer. Information regarding pathological complete response (pCR), event-free survival (EFS), overall survival (OS), and treatment-related adverse event (TRAE) were pooled to estimate the efficacy and safety. Hazard ratio, relative risk (RR) and their 95% confidence intervals (CIs) were calculated. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 22 eligible trials including 6134 women with resectable breast cancer, there were 11 randomized studies with 5574 patients. Pooled analysis on pCR (RR, 1.38; 95% CI, 1.20-1.58; <i>P</i> &lt;0.001), EFS (hazard ratio, 0.67; 95% CI, 0.54-0.81; <i>P</i> &lt;0.001), and OS (hazard ratio, 0.56; 95% CI, 0.35-0.91; <i>P</i> =0.01) revealed that ICB-based neoadjuvant therapy was associated with favorable outcomes over conventional treatment. Moreover, the benefits of EFS were independent of PD-L1 expression ( <i>P <sub>interaction</sub></i> =0.57) and pCR ( <i>P <sub>interaction</sub></i> =0.37) in neoadjuvant immunotherapy. However, combining ICB with conventional neoadjuvant treatment significantly increased the risk of high-grade TRAE (RR, 1.06; 95% CI, 1.01-1.12; <i>P</i> =0.03), serious TRAE (RR, 1.57; 95% CI, 1.26-1.94; <i>P</i> &lt;0.001), treatment discontinuation due to TRAE (RR, 1.47; 95% CI, 1.14-1.90; <i>P</i> =0.003), and potentially fatal adverse event (RR, 2.25; 95% CI, 0.80-6.31; <i>P</i> =0.12). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: The combination of ICB with conventional neoadjuvant treatment is associated with favorable clinical outcomes and importantly, increased grade 3+ toxicities. Clinicians should meticulously monitor patients to minimize the risk of treatment discontinuation in individuals with potentially curable breast cancer.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40213551/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">40213551</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11983617/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250411161211&v=2.18.0.post9+e462414">PMC11983617</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1537926>10.3389/fimmu.2025.1537926</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40213551</guid><pubDate> Fri, 11 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Yanle Ye</dc:creator><dc:creator> Zhishan Zhang</dc:creator><dc:creator> Hong Zhao</dc:creator><dc:creator> Bin Zhao</dc:creator><dc:date> 2025-04-11</dc:date><dc:source>免疫学领域</dc:source><dc:title>A system review of neoadjuvant immune checkpoint blockade for breast cancer</dc:title><dc:identifier> pmid:40213551</dc:identifier><dc:identifier> pmc:PMC11983617</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1537926</dc:identifier></item></channel></rss>